

Number of studies (%) (Total, n=87)	68 (78)	29 (33)	40 (46)	21 (24)	32 (37)	19 (22)	35 (40)	7 (8)	57 (66)	20 (23)	32 (37)	12 (14)	47 (54)	6 (7)	18 (21)
--	----------------	----------------	----------------	----------------	----------------	----------------	----------------	--------------	----------------	----------------	----------------	----------------	----------------	--------------	----------------

Shaded boxes represent the self-management components included in each study.

PF: pulmonary fibrosis; ADLs: activities of daily living; EOL: end-of-life

References

1. Albright K, Walker T, Baird S, et al. Seeking and sharing: why the pulmonary fibrosis community engages the web 2.0 environment. *BMC Pulm Med.* 2016; 16: 4.
2. Al Moamary MS. Impact of a pulmonary rehabilitation programme on respiratory parameters and health care utilization in patients with chronic lung diseases other than COPD. *East Mediterr Health J.* 2012; 18: 120-126.
3. Archibald N, Bakal JA, Richman-Eisenstat J, et al. Early integrated palliative care bundle impacts location of death in interstitial lung disease: a pilot retrospective study. *Am J Hosp Palliat Care.* 2021; 38: 104-113.
4. Arizono S, Taniguchi H, Sakamoto K, et al. Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: comparison with chronic obstructive pulmonary disease. *Sarcoidosis Vasc Diffuse Lung Dis.* 2017; 34: 283-289.
5. Bajwah S, Ross JR, Wells AU, et al. Palliative care for patients with advanced fibrotic lung disease: a randomised controlled phase II and feasibility trial of a community case conference. *Thorax.* 2015; 70: 830-839.
6. Bassi I, Guerrieri A, Carpano M, et al. Feasibility and efficacy of a multidisciplinary palliative approach in patients with advanced interstitial lung disease. A pilot randomised controlled trial. *Pulmonology.* 2021; <https://doi.org/10.1016/j.pulmoe.2021.11.004>.
7. Bischoff KE, Choi S, Su A, et al. Better together: a mixed-methods study of palliative care co-management for patients with interstitial lung disease. *J Palliat Med.* 2021; 24: 1823-1832.
8. Brunetti G, Malovini A, Maniscalco M, et al. Pulmonary rehabilitation in patients with interstitial lung diseases: correlates of success. *Respir Med.* 2021; 185: 106473.
9. Cerdán-de-las-Heras J, Balbino F, Løkke A, et al. Tele-rehabilitation program in idiopathic pulmonary fibrosis - a single-center randomized trial. *Int J Environ Res Public Health.* 2021; 18: 10016.

10. Chai GT, Neo HY, Abisheganaden J, et al. Impact of palliative care in end-of-life of fibrotic interstitial lung disease patients. *Am J Hosp Palliat Care*. 2022; 39: 1443-1451.
11. Chéhère B, Bougault V, Chenivresse C, et al. Cardiorespiratory adaptation during 6-minute walk test in fibrotic idiopathic interstitial pneumonia patients who did or did not respond to pulmonary rehabilitation. *Eur J Phys Rehabil Med*. 2019; 55: 103-112.
12. da Fontoura FF, Berton DC, Watte G, et al. Pulmonary rehabilitation in patients with advanced idiopathic pulmonary fibrosis referred for lung transplantation. *J Cardiopulm Rehabil Prev*. 2018; 38: 131-134.
13. Deniz S, Sahin H, Yalniz E. Does the severity of interstitial lung disease affect the gains from pulmonary rehabilitation? *Clinical Respir J*. 2018; 12: 2141-2150.
14. Devani P, Pinto N, Jain P, et al. Effect of pulmonary rehabilitation (PR) program in patients with interstitial lung disease (ILD) - Indian scenario. *J Assoc Physicians India*. 2019; 67: 28-33.
15. Dowman LM, McDonald CF, Hill CJ, et al. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. *Thorax*. 2017; 72: 610-619.
16. Duck A, Pigram L, Errhalt P, et al. IPF Care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe. *Adv Ther*. 2015; 32: 87-107.
17. Edwards C, Costello E, Cassidy N, et al. Use of the patientMpower app with home-based spirometry to monitor the symptoms and impact of fibrotic lung conditions: longitudinal observational study. *JMIR Mhealth Uhealth*. 2020; 8: e16158.
18. Elganady A, El Hoshy M, Eshmawey H, et al. Value of pulmonary rehabilitation in interstitial lung diseases. *Egypt J Chest Dis Tuberc*. 2020; 69: 542-548.
19. Ferreira G, Feuerman M, Spiegler P. Results of an 8-week, outpatient pulmonary rehabilitation program on patients with and without chronic obstructive pulmonary disease. *J Cardiopulm Rehabil*. 2006; 26: 54-60.
20. Ferreira A, Garvey C, Connors GL, et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. *Chest*. 2009; 135:442-447.

21. Fuschillo S, De Felice A, Elia A, et al. Effect of pulmonary rehabilitation on functional exercise capacity and hypoxemia in patients with interstitial lung diseases: a retrospective study. *Sarcoidosis Vasc Diffuse Lung Dis.* 2018; 35:245-251.
22. Gaunaurd IA, Gomez-Marin OW, Ramos CF, et al. Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program. *Respir care.* 2014; 59: 1872-1879.
23. Grongstad A, Spruit MA, Oldervoll LM, et al. Pulmonary rehabilitation in patients with pulmonary sarcoidosis: impact on exercise capacity and fatigue. *Respiration.* 2020; 99: 289-297.
24. Guler SA, Hur SA, Stickland MK, et al. Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study. *Thorax.* 2022; 77: 589-595.
25. Hoffman M, Mellerick C, Symons K, et al. Pulmonary rehabilitation for interstitial lung disease: referral and patient experiences. *Chron Respir Dis.* 2021; 18: 14799731211046022.
26. Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. *Thorax.* 2008; 63: 549-554.
27. Holland AE, Hill CJ, Glaspole I, et al. Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. *Respir Med.* 2012; 106: 429-435.
28. Huppmann P, Szczepanski B, Boensch M, et al. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. *Eur Respir J.* 2013; 42: 444-453.
29. Igai Y, Porter SE. Development and applicability of a dignity-centred palliative care programme for people with idiopathic pulmonary fibrosis: a qualitative-driven mixed methods study. *Nurs Open.* 2022; 10: 8-23.
30. Igarashi A, Iwanami Y, Sugino K, et al. Using 6-min walk distance expressed as a percentage of reference to evaluate the effect of pulmonary rehabilitation in elderly patients with interstitial lung disease. *J Cardiopulm Rehabil Prev.* 2018; 38: 342-347.

31. Jackson RM, Gómez-Marín OW, Ramos CF, et al. Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation. *Lung*. 2014; 192: 367-376.
32. Janssen K, Rosielle D, Wang Q, et al. The impact of palliative care on quality of life, anxiety, and depression in idiopathic pulmonary fibrosis: a randomized controlled pilot study. *Respir Res*. 2020; 21: 2: <https://doi.org/10.1186/s12931-019-1266-9>.
33. Jarosch I, Schneeberger T, Gloeckl R, et al. Short-term effects of comprehensive pulmonary rehabilitation and its maintenance in patients with idiopathic pulmonary fibrosis: a randomized controlled trial. *J Clin Med*. 2020; 9: 1567.
34. Kalluri M, Claveria F, Ainsley E, et al. Beyond idiopathic pulmonary fibrosis diagnosis: multidisciplinary care with an early integrated palliative approach is associated with a decrease in acute care utilization and hospital deaths. *J Pain Symptom Manage*. 2018; 55: 420-426.
35. Kalluri M, Lu-Song J, Younus S, et al. Health care costs at the end of life for patients with idiopathic pulmonary fibrosis. Evaluation of a pilot multidisciplinary collaborative interstitial lung disease clinic. *Ann Am Thorac Soc*. 2020; 17: 706-713.
36. Kalluri M, Younus S, Archibald N, et al. Action plans in idiopathic pulmonary fibrosis: a qualitative study—'I do what I can do'. *BMJ Support Palliat Care*. 2021: <http://doi.org/10.1136/bmjspcare-2020-002831>.
37. Kaymaz D, Ergun P, Candemir I, et al. Pulmonary rehabilitation in interstitial lung diseases. *Tuberk Toraks*. 2013; 61: 295-302.
38. Kerti M, Kelemen K, Varga J. The effectiveness of pulmonary rehabilitation in comparison interstitial lung diseases and idiopathic pulmonary fibrosis. *J Pulm Respir Med*. 2018; 8: 1000475.
39. Keyser RE, Woolstenhulme JG, Chin LMK, et al. Cardiorespiratory function before and after aerobic exercise training in patients with interstitial lung disease. *J Cardiopulm Rehabil Prev*. 2015; 35: 47-55.
40. Khor YH, Saravanan K, Holland AE, et al. A mixed-methods pilot study of handheld fan for breathlessness in interstitial lung disease. *Sci Rep*. 2021; 11: 6874.

41. Kozu R, Senjyu H, Jenkins SC, et al. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. *Respiration*. 2011; 81: 196-205.
42. Ku V, Janmeja AK, Aggarwal D, et al. Pulmonary rehabilitation in patients with interstitial lung diseases in an outpatient setting: a randomised controlled trial. *Indian J Chest Dis Allied Sci*. 2017; 59: 75-80.
43. Lindell KO, Olshansky E, Song M-K, et al. Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners. *Heart Lung*. 2010; 39: 304-313.
44. Lindell KO, Klein SJ, Veatch MS, et al. Nurse-led palliative care clinical trial improves knowledge and preparedness in caregivers of patients with idiopathic pulmonary fibrosis. *Ann Am Thorac Soc*. 2021; 18: 1811-1821.
45. Lingner H, Buhr-Schinner H, Hummel S, et al. Short-term effects of a multimodal 3-week inpatient pulmonary rehabilitation programme for patients with sarcoidosis: the ProKaSaRe study. *Respiration*. 2018; 95: 343-353.
46. Lo HYLK, Luo XY, Lau CMJ, et al. Pilot project in developing community rehabilitation service for migrant workers suffering from pneumoconiosis in Mainland China. *Work*. 2007; 30: 33-38.
47. Magnani D, Lenoci G, Balduzzi S, et al. Effectiveness of support groups to improve the quality of life of people with idiopathic pulmonary fibrosis a pre-post test pilot study. *Acta Biomed*. 2017; 88: 5-12.
48. Matsuo S, Okamoto M, Ikeuchi T, et al. Early intervention of pulmonary rehabilitation for fibrotic interstitial lung disease is a favorable factor for short-term improvement in health-related quality of life. *J Clin Med*. 2021; 10: 3153.
49. Moor CC, Mostard RLM, Grutters JC, et al. Home monitoring in patients with idiopathic pulmonary fibrosis: a randomized controlled trial. *Am J Respir Crit Care Med*. 2020; 202: 393-401.

50. Moor CC, Leuven Slv, Wijssenbeek MS, et al. Feasibility of online home spirometry in systemic sclerosis-associated interstitial lung disease: a pilot study. *Rheumatol*. 2021; 60: 2467-2471.
51. Naji NA, Connor MC, Donnelly SC, et al. Effectiveness of pulmonary rehabilitation in restrictive lung disease. *J Cardiopulm Rehabil*. 2006; 26: 237-243.
52. Nasrat SA, El-Hady AAA, Hafiz HA, et al. The efficacy of pulmonary rehabilitation combined with threshold inspiratory muscle training and upper extremities exercises in patients with interstitial lung diseases. *Syst Rev Pharm*. 2021; 12: 527-533.
53. Naz I, Ozalevli S, Ozkan S, et al. Efficacy of a structured exercise program for improving functional capacity and quality of life in patients with stage 3 and 4 sarcoidosis: a randomized controlled trial. *J Cardiopulm Rehabil Prev*. 2018; 38: 124-130.
54. Near AM, Burudpakdee C, Viswanathan S, et al. Effect of a patient support program for idiopathic pulmonary fibrosis patients on medication persistence: a retrospective database analysis. *Adv Ther*. 2021; 38: 3888-3899.
55. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. *Respirology*. 2008; 13: 394-399.
56. Nolan CM, Polgar O, Schofield SJ, et al. Pulmonary rehabilitation in idiopathic pulmonary fibrosis and COPD: a propensity-matched real-world study. *Chest*. 2022; 161: 728-737.
57. Ochmann U, Kotschy-Lang N, Raab W, et al. Long-term efficacy of pulmonary rehabilitation in patients with occupational respiratory diseases. *Respiration*. 2012; 84: 396-405.
58. Ozalevli S, Karaali HK, Ilgin D, et al. Effect of home-based pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. *Multidiscip Respir Med*. 2010; 5: 31-37.
59. Perez-Bogerd S, Wuyts W, Barbier V, et al. Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. *Respir Res*. 2018; 19: 182.
60. Prajapat B, Sandhya AS, Menon B, et al. Effect of pulmonary rehabilitation on systemic inflammation muscle mass and functional status in interstitial lung diseases. *Int J Sci Res*. 2016; 5: 760-766.

61. Rammaert B, Leroy S, Cavestri B, et al. Home-based pulmonary rehabilitation in idiopathic pulmonary fibrosis. *Rev Mal Respir.* 2011; 28: e52-57.
62. Rifaat N, Anwar E, Ali YM, et al. Value of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. *Egypt J Chest Dis Tuberc.* 2014; 63: 1013-1017.
63. Ryerson CJ, Cayou C, Topp F, et al. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. *Respir Med.* 2014; 108: 203-210.
64. Salhi B, Troosters T, Behaegel M, et al. Effects of pulmonary rehabilitation in patients with restrictive lung diseases. *Chest.* 2010; 137: 273-279.
65. Sanchez-Ramirez DC. Impact of pulmonary rehabilitation services in patients with different lung diseases. *J Clin Med.* 2022; 11: 407.
66. Satsuma Y, Ikesue H, Kusuda K, et al. Effectiveness of pharmacist-physician collaborative management for patients with idiopathic pulmonary fibrosis receiving pirfenidone. *Front Pharmacol.* 2020; 11: 529654.
67. Sciriha A, Lungaro-Mifsud S, Fsadni P, et al. Pulmonary rehabilitation in patients with interstitial lung disease: the effects of a 12-week programme. *Respir Med.* 2019; 146: 49-56.
68. Sgalla G, Cerri S, Ferrari R, et al. Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy. *BMJ Open Respir Res.* 2015; 2: e00065.
69. Sharp C, McCabe M, Hussain MJ, et al. Duration of benefit following completion of pulmonary rehabilitation in interstitial lung disease-an observational study. *QJM.* 2017; 110: 17-22.
70. Shen L, Zhang Y, Su Y, et al. New pulmonary rehabilitation exercise for pulmonary fibrosis to improve the pulmonary function and quality of life of patients with idiopathic pulmonary fibrosis: a randomized control trial. *Ann Palliat Med.* 2021; 10: 7289-7297.
71. Shimoda M, Takao S, Kokutou H, et al. In-hospital pulmonary rehabilitation after completion of primary respiratory disease treatment improves physical activity and ADL performance: a prospective intervention study. *Medicine.* 2021; 100: e28151.

72. Stanziola AA, Salzano A, D'Angelo R, et al. Idiopathic pulmonary fibrosis telemedicine management during COVID-19 outbreak. *Open Med.* 2022; 17: 689-693.
73. Swigris JJ, Fairclough DL, Morrison M, et al. Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis. *Respir Care.* 2011; 56: 783-789.
74. Talwar A, Sahni S, John S, et al. Effects of pulmonary rehabilitation on fatigue severity scale in patients with lung disease. *Pneumonol Alergol Pol.* 2014; 82: 534-540.
75. Thombs BD, Kwakkenbos L, Levis B, et al. Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, randomised, controlled trial. *Lancet Rheumatol.* 2021; 3: e427-437.
76. Tikellis G, Lee JYT, Corte TJ, et al. Peer connect service for people with pulmonary fibrosis in Australia: participants' experiences and process evaluation. *Respirology.* 2020; 25: 1053-1059.
77. Tonelli R, Cocconcelli E, Lanini B, et al. Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: a multicenter prospective study. *BMC Pulm Med.* 2017; 17: 130.
78. Trivedi SJ. Effect of pulmonary rehabilitation on functional capacity of lungs and dyspnea in patient with silicosis in Anand district of Gujarat. *Indian J Physiother Occup Ther.* 2017; 11: 207-209.
79. Tsang EW, Kwok H, Chan AKY, et al. Outcomes of community-based and home-based pulmonary rehabilitation for pneumoconiosis patients: a retrospective study. *BMC Pulm Med.* 2018; 18: 133.
80. Vainshelboim B, Oliveira J, Yehoshua L, et al. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. *Respiration.* 2014; 88: 378-388.
81. Vainshelboim B, Oliveira J, Fox BD, et al. Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. *Lung.* 2015; 193: 345-354.

82. Vainshelboim B, Fox BD, Kramer MR, et al. Short-term improvement in physical activity and body composition after supervised exercise training program in idiopathic pulmonary fibrosis. *Arch Phys Med Rehabil.* 2016; 97: 788-797.
83. Wallaert B, Duthoit L, Drumez E, et al. Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias. *ERJ Open Res.* 2019; 5: 00045-2019.
84. Wallaert B, Kyheng M, Labreuche J, et al. Long-term effects of pulmonary rehabilitation on daily life physical activity of patients with stage IV sarcoidosis: a randomized controlled trial. *Respir Med Res.* 2020; 77: 1-7.
85. Zaki S, Moiz JA, Mujaddadi A, et al. Does inspiratory muscle training provide additional benefits during pulmonary rehabilitation in people with interstitial lung disease? A randomized control trial. *Physiother Theory Pract.* 2022; 39: 518-528.
86. Zhang Z, Tian Y, Yang J. Effects of pulmonary rehabilitation therapy combined with conventional drugs on BODE and pulmonary function indexes in elderly patients with interstitial pneumonia. *Pak J Med Sci.* 2022; 38: 1703-1707.
87. Zhou M, Zhang H, Li F, et al. Pulmonary Daoyin as a traditional Chinese medicine rehabilitation programme for patients with IPF: a randomized controlled trial. *Respirology.* 2021; 26: 360-369.